EAM Investors’s Armata Pharmaceuticals ARMP Stock Holding History

EAM Investors’s Portfolio ARMP Stock Details ARMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,955	Closed	-$624K	–	275
2026 Q1	$624K	Buy	+60,955	New	+$513K	0.07%	245

Other funds holding ARMP

MAM

Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

EAM Investors's ARMP Position: Q2 2026 in Review

EAM Investors sold out of Armata Pharmaceuticals (ARMP) in Q2 2026, closing a stake of 60,955 shares — an estimated $624K sold.

EAM Investors first reported a position in ARMP in Q1 2026 and held it in 1 quarter. The position peaked at $624K in Q1 2026. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

EAM Investors reported no remaining Armata Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
EAM Investors sold 60,955 Armata Pharmaceuticals shares in Q2 2026, an estimated $624K.
EAM Investors first reported a position in Armata Pharmaceuticals in Q1 2026 and held it in 1 quarter.
EAM Investors's Armata Pharmaceuticals position peaked at $624K in Q1 2026.
53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.